Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipid Sciences has said that the company's LSI-518P shows the ability to reduce the progression of atherosclerosis by 20% after four weeks of treatment and by 32% after eight weeks of treatment when compared to a placebo group in a well-accepted, Apo E knockout mouse model.
Subscribe to our email newsletter
Because the initial design goals of the HDL mimetic peptide therapeutic program have now been met, the company will now move rapidly to validate other key cardio-protective characteristics of LSI-518P and begin conducting a comprehensive series of toxicology studies in the next phase of the LSI-518P development program supportive of an IND filing and initiation of Phase I trials.
Bryan Brewer, chief scientific director of Lipid Sciences, said: “This study confirms, in a well-accepted animal model, that LSI-518P is highly effective in reducing the build-up of atherosclerotic plaque in the arterial wall.”